Scholarlink

<p>The proportion of relative influenza vaccine efficacy (rVE) mediated by post-vaccination hemagglutination inhibition (HAI) and microneutralization (MN) antibody titers has not been evaluated. We compared rVE by influenza vaccine type and HAI and MN antibody titer against symptomatic influenza A(H3N2) infection in a randomized immunogenicity trial of quadrivalent cell culture-based (ccIIV4), recombinant (RIV4), and egg-based (eIIV4) influenza vaccines in US healthcare personnel, and estimated proportions of rVE mediated by antibody titers using causal mediation analysis. Cumulative influenza A(H3N2) incidence was 3.2%, 1.3% and 1% among ccIIV, eIIV4 and RIV4 recipients, respectively. Age-adjusted rVE estimates were not statistically significant. Higher MN and HAI titers against A(H3N2) vaccine and circulating viruses explained 97.9% and 15.8%, respectively, of rVE for RIV4 compared with ccIIV4, versus 1.7% and 12.6% of rVE for eIIV4 compared with ccIIV4, indicating MN titers to be used as correlates of protection against A(H3N2) for comparisons between cell-based influenza vaccines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hemagglutination-inhibition and microneutralization antibody titers as mediators of protection for cell-based and recombinant influenza vaccines

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Shuyi Zhong,
  • Wey Wen Lim,
  • Faith Ho,
  • Manjusha Gaglani,
  • Allison L. Naleway,
  • Fatimah S. Dawood,
  • Min Z. Levine,
  • Kelsey Sumner,
  • Brendan Flannery,
  • Benjamin J. Cowling

摘要

The proportion of relative influenza vaccine efficacy (rVE) mediated by post-vaccination hemagglutination inhibition (HAI) and microneutralization (MN) antibody titers has not been evaluated. We compared rVE by influenza vaccine type and HAI and MN antibody titer against symptomatic influenza A(H3N2) infection in a randomized immunogenicity trial of quadrivalent cell culture-based (ccIIV4), recombinant (RIV4), and egg-based (eIIV4) influenza vaccines in US healthcare personnel, and estimated proportions of rVE mediated by antibody titers using causal mediation analysis. Cumulative influenza A(H3N2) incidence was 3.2%, 1.3% and 1% among ccIIV, eIIV4 and RIV4 recipients, respectively. Age-adjusted rVE estimates were not statistically significant. Higher MN and HAI titers against A(H3N2) vaccine and circulating viruses explained 97.9% and 15.8%, respectively, of rVE for RIV4 compared with ccIIV4, versus 1.7% and 12.6% of rVE for eIIV4 compared with ccIIV4, indicating MN titers to be used as correlates of protection against A(H3N2) for comparisons between cell-based influenza vaccines.